Tag: Viaskin® Peanut
DBV Announces Promising 2-Year Results from Ongoing Viaskin “Peanut Patch” Toddler...
81.3% of subjects who completed the oral food challenge reached an eliciting dose of ≥1,000 mg after 24 months of treatment.
DBV Outlines Path to Regulatory Approval of Viaskin Peanut Patch
Are Viaskin therapies finally on the horizon?
FDA Removes Hold Allowing DBV’s Pivotal Phase 3 Peanut Patch Trial...
The phase 3 trial of the modified Viaskin Peanut patch has been cleared for commencement.
Skin Patch Immunotherapy Determined Safe and Effective in Toddlers With Peanut...
According to research presented at this year's #ACAAI22 meeting.
Private Law Firm to Investigate Claims on Behalf of Investors in...
It is unknown how this development will affect the ability of the company to eventually offer Viaskin Peanut as an FDA approved therapy.
FDA Issues Partial Hold on DBV Viaskin Peanut Patch Trial
Another delay for the long-awaited therapy.
DBV Begins Phase 3 Study of Redesigned Viaskin Peanut Patch in...
Viaskin is testing a new version of their patch designed to address the FDA's concerns.
DBV Announces Positive Topline Results from Phase 3 Trial of Viaskin...
Viaskin Peanut demonstrated a statistically significant treatment effect with 67.0% of subjects meeting the treatment responder criteria after 12 months.
CEO Expects Approval and Launch of Intranasal Emergency Epinephrine Spray by...
The market for epinephrine delivery may expand to include non-needle alternatives next year.
Viaskin Peanut Patch Therapy Delayed Further as DBV Readies Another Phase...
The patch therapy remains in regulatory limbo.
